Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Increased serum CA 19.9 in bronchiectasis].

J Yango1, T Pieters, E Coche

  • 1Service de Médecine Interne, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium.

Revue Des Maladies Respiratoires
|February 22, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Secondary organizing pneumonia associated with protracted COVID: A case series.

Infectious diseases now·2024
Same author

Preliminary experience of CT imaging of the ischaemic brain penumbra through spectral processing of multiphasic CTA datasets.

Scientific reports·2023
Same author

Fungal pneumonia in kidney transplant recipients.

Respiratory medicine·2021
Same author

Benefit of dual-layer spectral CT in emergency imaging of different organ systems.

Clinical radiology·2020
Same author

Post-mortem CT angiography of mesenteric vessels using cinematic rendering vision.

Diagnostic and interventional imaging·2019
Same author

Virtual unenhanced phase with spectral dual-energy CT: Is it an alternative to conventional true unenhanced phase for abdominal tissues?

Diagnostic and interventional imaging·2019
Same journal

[French version of the guidelines for connective tissue disease-associated ILD].

Revue des maladies respiratoires·2026
Same journal

[Pulmonary expression of an asymptomatic lysosomal storage disorder].

Revue des maladies respiratoires·2026
Same journal

[Factors associated with FEV1 evolution in cystic fibrosis patients treated by CFTR modulator tritherapy].

Revue des maladies respiratoires·2026
Same journal

[Subacute pulmonary coccidioidomycosis: A differential diagnosis of lung cancer].

Revue des maladies respiratoires·2026
Same journal

[Relevance of the ACT score in severe asthma with obesity: A pilot study].

Revue des maladies respiratoires·2026
Same journal

[Automated analysis of mandibular movements for the screening of obstructive sleep apnea].

Revue des maladies respiratoires·2026
See all related articles

Elevated cancer antigen 19.9 (CA 19.9) levels, typically a marker for pancreatic cancer, can occur in benign lung conditions like bronchiectasis. This case highlights that CA 19.9 is not a reliable screening tool for cancer.

Area of Science:

  • Oncology
  • Pulmonology
  • Clinical Diagnostics

Background:

  • Carbohydrate antigen 19.9 (CA 19.9) is a sensitive marker for pancreatic adenocarcinoma.
  • Elevated CA 19.9 levels can also be observed in non-neoplastic conditions, including benign pulmonary diseases.
  • Significantly increased CA 19.9 in bronchiectasis is rare.

Observation:

  • A 67-year-old woman incidentally presented with serum CA 19.9 levels over 1500 U/ml (normal <37 U/ml).
  • Extensive investigations ruled out digestive malignancy.
  • Positron emission tomography, CT scans, and bronchoscopy revealed bilateral bronchiectasis with Haemophilus influenzae infection.

Findings:

  • Antibiotic treatment led to a partial decrease in CA 19.9 levels.
  • CA 19.9 remained abnormally elevated for over two years despite treatment.

Related Experiment Videos

  • The findings suggest a strong association between bronchiectasis and persistently high CA 19.9 levels.

    • Implications:

    • This case underscores the limitations of using CA 19.9 as a standalone screening test for pancreatic cancer.
    • Tumor markers can yield false positives in the presence of benign conditions like bronchiectasis.
    • Relying solely on CA 19.9 for cancer screening may lead to unnecessary anxiety and further invasive testing.